Pacira BioSciences Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: Oct-2026Ownership Structure
Ownership Analysis
Pacira has a straightforward public-company chain: shareholders elect the board, the board oversees management, and operating subsidiaries house commercial products and acquired technology. There is no dual-class structure, controlling parent or founder block that can override the common vote. We would score this structure on control clarity, minority-holder protection and the board’s willingness to change course when returns disappoint. The decisive evidence will be free cash flow after required investment, not adjusted earnings alone.That simplicity does not remove agency risk. The company has deployed capital into MyoScience, Flexion and GQ Bio Therapeutics while EXPAREL still generated 79% of 2025 revenue, making portfolio diversification and acquisition returns central tests of board judgment. The relevant CFA lens is agency risk: managers control resources, while outside owners bear the residual economic outcome. We would link that judgment to return on invested capital, leverage and the durability of customer demand.The 2026 proxy contest created a real-time governance test. Incumbents kept their seats, but the campaign increased scrutiny of launch execution, research spending and the pace of value creation from acquired assets. A clean chain of authority helps, but it earns a valuation premium only when reinvestment and financing decisions clear the cost of capital. Downside analysis should include a weaker demand case and a higher refinancing cost, even where current liquidity is comfortable.We see the structure as shareholder accountable but commercially concentrated. Independent ownership preserves strategic optionality, including partnerships or a sale, while also requiring Pacira to carry the full cost of commercial infrastructure and pipeline risk. We would monitor voting outcomes, board refreshment and capital deployment together because none of those indicators is sufficient alone. Per-share value creation remains the governing standard because growth without adequate returns can destroy economic value.
Direct Owners
Institutional Shareholders
Shareholder Analysis
DOMA’s reported 7.5% stake was large enough to nominate directors and frame a change case, yet too small to command an outcome. Its influence came from persuasion and coalition building, not legal control. Large holders can improve oversight, yet their index, active or strategic mandates create different incentives and different engagement intensity. The decisive evidence will be free cash flow after required investment, not adjusted earnings alone.Other holdings are spread among institutions whose mandates differ. Passive funds primarily vote stewardship policies, while active health-care investors can engage on capital allocation, product concentration and management credibility. We treat reported percentages as dated snapshots rather than permanent control because securities lending and portfolio rebalancing can change influence. We would link that judgment to return on invested capital, leverage and the durability of customer demand.The company-backed slate winning in June 2026 does not close the governance issue. A contested vote can affect board behavior even when dissidents lose, particularly if the support split indicates dissatisfaction among long-only owners. The analytical question is whether concentrated holders challenge weak decisions or merely provide stable votes for the incumbent board. Downside analysis should include a weaker demand case and a higher refinancing cost, even where current liquidity is comfortable.We would read the register together with turnover and new 13D or 13G filings. A concentrated activist position can increase accountability, but a crowded exit after an operating miss can also amplify share-price volatility. We would compare ownership filings with meeting results and engagement disclosures before assigning any governance benefit. Per-share value creation remains the governing standard because growth without adequate returns can destroy economic value.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|---|---|
| EXPAREL | Product | Long-acting local analgesic based on liposome bupivacaine |
| ZILRETTA | Product | Extended-release corticosteroid injection for knee osteoarthritis pain |
| iovera | Product | Handheld cryoanalgesia system |
| Pacira Therapeutics | Subsidiary | Commercial and development operations acquired with Flexion |
| GQ Bio Therapeutics | Subsidiary | Gene-therapy platform acquired in 2025 |
Portfolio Analysis
EXPAREL is the economic center of Pacira. Its $575.1 million of 2025 sales represented 79% of group revenue, so procedure adoption, contracting and competitive positioning matter more to near-term value than the number of names in the portfolio. We value the portfolio by customer economics and cash generation, separating owned assets from licensed names, products or service lines. The decisive evidence will be free cash flow after required investment, not adjusted earnings alone.ZILRETTA contributes a second commercial stream in knee osteoarthritis, while iovera offers a device-based approach to pain. These products broaden call points and clinical settings, but they do not yet match EXPAREL’s scale. Brand breadth adds value only when distribution, pricing, data or procurement advantages exceed the cost of maintaining separate propositions. We would link that judgment to return on invested capital, leverage and the durability of customer demand.GQ Bio Therapeutics adds PCRX-201 and a gene-therapy platform at an earlier risk stage. It can extend the duration of Pacira’s growth opportunity, yet it also introduces clinical, regulatory and manufacturing uncertainty before material revenue. We would test concentration with segment revenue, retention and margin evidence instead of counting names in the portfolio. Downside analysis should include a weaker demand case and a higher refinancing cost, even where current liquidity is comfortable.We would avoid assigning equal value to commercial products and pipeline assets. EXPAREL merits a cash-flow framework, ZILRETTA and iovera require adoption analysis, and GQ programs call for probability-adjusted valuation. The key valuation issue is whether the leading franchise funds attractive reinvestment or subsidizes weaker extensions. Per-share value creation remains the governing standard because growth without adequate returns can destroy economic value.
Market Share & Competitors
| Company | Market Share | Revenue | Key Strength |
|---|---|---|---|
| Pacira BioSciences ★ | N/A | $726.4M | Non-opioid pain-management portfolio |
| Heron Therapeutics | N/A | $158.7M | Extended-release postoperative analgesia |
| Hikma Pharmaceuticals | N/A | $3.16B | Injectable generics scale |
| Organon | N/A | $6.40B | Established hospital and women’s-health channels |
Competitive Analysis
Pacira competes against branded extended-release products, generic local anesthetics, systemic analgesics and established clinical practice. The customer decision depends on total episode economics, pain control, workflow and reimbursement, not solely on drug price. We frame competitive advantage through pricing power, switching cost, scale economy and customer concentration rather than market narrative. The decisive evidence will be free cash flow after required investment, not adjusted earnings alone.EXPAREL benefits from clinical familiarity and broad procedure use, yet hospitals and physicians can choose inexpensive generic bupivacaine or competing regimens. Evidence quality and contracting discipline are therefore essential to defend utilization. A credible moat should appear in stable retention, superior unit economics or returns on invested capital through more than one demand cycle. We would link that judgment to return on invested capital, leverage and the durability of customer demand.ZILRETTA faces alternatives in osteoarthritis care, while iovera must earn a place beside drugs and procedures. The portfolio creates multiple routes to the clinician, but each product still requires distinct economic proof. We also distinguish structural threats from cyclical weakness because the correct valuation response differs sharply between them. Downside analysis should include a weaker demand case and a higher refinancing cost, even where current liquidity is comfortable.We would watch unit volume, net price, account penetration and repeat utilization. Revenue growth driven by deeper adoption is higher quality than growth dependent on discounting or channel inventory. Our monitoring set emphasizes share, price versus volume, service quality and the cost required to defend the franchise. Per-share value creation remains the governing standard because growth without adequate returns can destroy economic value.
Acquisitions
| Company Acquired | Deal Value | Year | Description |
|---|---|---|---|
| MyoScience | $120.0M | 2019 | Added the iovera cryoanalgesia platform |
| Flexion Therapeutics | $578.8M | 2021 | Added ZILRETTA and a musculoskeletal commercial platform |
| GQ Bio Therapeutics | N/A | 2025 | Added PCRX-201 and a gene-therapy platform |
Acquisitions Analysis
MyoScience brought iovera in 2019 for $120 million upfront, giving Pacira a non-drug technology that complements perioperative pain care. The strategic logic was channel adjacency, though the asset remains much smaller than EXPAREL. We judge each deal against its full purchase consideration, integration cost, incremental cash flow and the return required for its risk. The decisive evidence will be free cash flow after required investment, not adjusted earnings alone.Flexion was the largest portfolio step. The $578.8 million 2021 purchase added ZILRETTA, commercial staff and development capabilities, but it also raised the hurdle for revenue growth and integration savings to justify invested capital. Strategic fit is useful, but we would not credit synergy until it appears in margins, retention, capacity utilization or reduced capital intensity. We would link that judgment to return on invested capital, leverage and the durability of customer demand.The 2025 GQ Bio Therapeutics purchase moved Pacira into gene therapy through PCRX-201. Consideration was not publicly framed as a headline cash price, so milestones, research commitments and probability of technical success matter more than a single deal figure. Balance-sheet capacity also matters because an acquisition can be operationally sound while still transferring value from shareholders to sellers. Downside analysis should include a weaker demand case and a higher refinancing cost, even where current liquidity is comfortable.Taken together, the deals show deliberate diversification beyond EXPAREL. We would credit management only as acquired products generate incremental cash flow and lower concentration, rather than treating added platforms as value by themselves. Our post-deal review would reconcile management promises with realized revenue, expense savings, impairments and leverage reduction. Per-share value creation remains the governing standard because growth without adequate returns can destroy economic value.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Pacira’s current form began with injectable assets separated from SkyePharma and financed privately. That origin created an independent specialty-pharma platform centered on delivery technology rather than a broad inherited portfolio. Corporate history matters because it reveals how management handles integration, leverage, divestitures and accountability after strategic change. The decisive evidence will be free cash flow after required investment, not adjusted earnings alone.The 2019 name change from Pacira Pharmaceuticals to Pacira BioSciences signaled a wider ambition before the company bought Flexion. It did not itself change control, but it anticipated expansion beyond a single-product identity. We would separate accounting scale from economic improvement by tracking per-share cash flow and returns on the capital committed. We would link that judgment to return on invested capital, leverage and the durability of customer demand.Flexion’s 2021 merger was the most consequential corporate combination because it added ZILRETTA and a second commercial organization. The integration expanded scale while making acquisition discipline more visible to shareholders. Prior combinations also shape today’s systems, contracts and culture, which can either support execution or consume management attention. Downside analysis should include a weaker demand case and a higher refinancing cost, even where current liquidity is comfortable.GQ Bio Therapeutics in 2025 extended the history into gene therapy. We see an evolution from product company to multi-platform developer, with rising scientific opportunity matched by greater execution complexity. The useful lesson is not that past deals succeeded or failed, but which operating assumptions proved reliable. Per-share value creation remains the governing standard because growth without adequate returns can destroy economic value.
Ownership History
Ownership History Analysis
Private backing initially funded development of the former SkyePharma injectable assets. The 2011 initial public offering then transferred price discovery and governance to public markets while preserving management’s ability to pursue an independent strategy. The ownership sequence shows who supplied capital, who exercised control and which governance constraints accompanied each phase of growth. The decisive evidence will be free cash flow after required investment, not adjusted earnings alone.Public ownership financed commercialization of EXPAREL and later acquisitions. As the product became dominant, shareholders increasingly judged management on diversification and the conversion of revenue scale into sustained cash returns. We use that record to assess management incentives, board independence and the probability that minority investors receive proportionate benefits. We would link that judgment to return on invested capital, leverage and the durability of customer demand.The 2026 DOMA campaign marked the clearest challenge to incumbent direction. Although the dissident slate did not win, the event demonstrated that dispersed ownership can still produce organized oversight when a holder commits capital and resources. Transitions in ownership often reset leverage and strategic priorities, so historical context improves interpretation of current financial ratios. Downside analysis should include a weaker demand case and a higher refinancing cost, even where current liquidity is comfortable.As of October 2026, control remains with the shareholder body rather than a strategic buyer. The next phase will be judged on commercial execution, pipeline prioritization and whether governance responds to the concerns surfaced during the contest. Our forward view gives greatest weight to the present charter, shareholder base and demonstrated capital-allocation behavior. Per-share value creation remains the governing standard because growth without adequate returns can destroy economic value.
Ownership Explained
Pacira BioSciences is a widely held Nasdaq company with one vote per common share and no controlling founder or parent. Public shareholders own the residual equity, while the board appoints management and oversees a portfolio led by EXPAREL. DOMA Perpetual Capital Management became the most visible active holder during the 2026 proxy contest, reporting a 7.5% position.The June 2026 annual meeting preserved the company-backed board slate, but the contest made capital allocation, commercial execution and board accountability central ownership issues. Pacira remains independent as of October 2026. Its subsidiaries hold product, development and acquired operating assets, while shareholders retain ultimate voting authority through director elections and other matters submitted for approval.
Pacira shareholders own a focused pain-management company rather than a diversified drug group. That concentration gives them direct participation in EXPAREL economics, but it also leaves valuation sensitive to procedure volumes, reimbursement, patent outcomes and the pace at which newer assets reduce reliance on one product. For us, the practical test is whether governance converts strategic authority into per-share value without weakening financial flexibility. The decisive evidence will be free cash flow after required investment, not adjusted earnings alone.No parent can absorb a commercial setback or supply capital on preferential terms. Pacira must fund sales investment, trials, manufacturing and acquisitions from its own cash generation and financing capacity, so every strategic choice competes for the same balance-sheet resources. We would therefore read ownership through capital allocation, disclosure quality, board accountability and the cash economics available to each security holder. We would link that judgment to return on invested capital, leverage and the durability of customer demand.The contested 2026 meeting shows that a meaningful holder can force a public debate without possessing control. DOMA influenced the agenda, yet the company slate prevailed, confirming that authority remains dispersed across institutions, index funds, active managers and retail holders. The structure matters most when operating conditions change, since control determines who can reset spending, financing and portfolio priorities. Downside analysis should include a weaker demand case and a higher refinancing cost, even where current liquidity is comfortable.For a minority investor, ownership therefore combines economic exposure with conventional public-company voting rights. The shares provide liquidity and a voice, but no investor can direct pricing, research priorities or acquisition policy without broader support. Our conclusion depends on evidence from returns, leverage and cash conversion, not on the legal label attached to the owner. Per-share value creation remains the governing standard because growth without adequate returns can destroy economic value.